SW
BMY icon

SlateStone Wealth’s Bristol-Myers Squibb BMY Stock Holding History

SlateStone Wealth’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$670K Sell
11,624
-79
-0.7% -$4.54K 0.05% 206
2026
Q1 		$710K Sell
11,703
-487
-4% -$28.4K 0.06% 190
2025
Q4 		$658K Buy
+12,190
New +$586K 0.06% 196
2025
Q2 		– Sell
-4,815
Closed -$294K – 292
2025
Q1 		$294K Buy
4,815
+900
+23% +$52.5K 0.03% 246
2024
Q4 		$221K Sell
3,915
-118
-3% -$6.59K 0.02% 267
2024
Q3 		$209K Buy
+4,033
New +$189K 0.02% 269
2024
Q2 		– Sell
-5,295
Closed -$287K – 286
2024
Q1 		$287K Buy
5,295
+1
+0% +$51 0.03% 238
2023
Q4 		$272K Sell
5,294
-498
-9% -$26.1K 0.04% 206
2023
Q3 		$336K Sell
5,792
-539
-9% -$33K 0.05% 188
2023
Q2 		$405K Buy
6,331
+1
+0% +$67 0.08% 151
2023
Q1 		$439K Sell
6,330
-804
-11% -$56.7K 0.09% 152
2022
Q4 		$513K Sell
7,134
-4,875
-41% -$368K 0.12% 113
2022
Q3 		$854K Buy
12,009
+1
+0% +$73 0.23% 89
2022
Q2 		$925K Buy
12,008
+21
+0.2% +$1.6K 0.24% 83
2022
Q1 		$875K Sell
11,987
-27
-0.2% -$1.81K 0.2% 85
2021
Q4 		$749K Buy
12,014
+5,241
+77% +$307K 0.16% 97
2021
Q3 		$401K Sell
6,773
-52
-0.8% -$3.42K 0.09% 126
2021
Q2 		$456K Sell
6,825
-159
-2% -$10.4K 0.1% 122
2021
Q1 		$441K Buy
6,984
+2,821
+68% +$176K 0.11% 117
2020
Q4 		$258K Sell
4,163
-11,889
-74% -$731K 0.06% 146
2020
Q3 		$968K Buy
16,052
+232
+1% +$14K 0.21% 100
2020
Q2 		$930K Buy
15,820
+10,211
+182% +$611K 0.21% 97
2020
Q1 		$312K Sell
5,609
-1,249
-18% -$76.3K 0.09% 139
2019
Q4 		$440K Buy
+6,858
New +$393K 0.1% 144
2019
Q2 		– Sell
-4,200
Closed -$200K – 173
2019
Q1 		$200K Buy
+4,200
New +$209K 0.06% 156

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SlateStone Wealth's BMY Position: Q2 2026 in Review

SlateStone Wealth reduced its Bristol-Myers Squibb (BMY) stake by 0.68% in Q2 2026, selling an estimated $4.54K and leaving 11,624 shares worth $670K. The position accounts for 0.05% of the portfolio, ranked #206.

SlateStone Wealth first reported a position in BMY in Q1 2019 and has held it in 25 quarters since. The position peaked at $968K in Q3 2020. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • SlateStone Wealth held 11,624 shares of Bristol-Myers Squibb worth $670K as of Q2 2026.
  • SlateStone Wealth sold 79 Bristol-Myers Squibb shares in Q2 2026, an estimated $4.54K.
  • Bristol-Myers Squibb made up 0.05% of SlateStone Wealth's portfolio in Q2 2026, its #206 holding.
  • SlateStone Wealth first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 25 quarters since.
  • SlateStone Wealth's Bristol-Myers Squibb position peaked at $968K in Q3 2020.
  • 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on SlateStone Wealth's 13F filing for Q2 2026, filed 20 Jul 2026.